SPEN
SPEN (Msx2-interacting protein) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 5 more.
Overview
May serve as a nuclear matrix platform that organises and integrates transcriptional responses. In osteoblasts, supports transcription activation: synergises with RUNX2 to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE). Has also been shown to be an essential corepressor protein, which probably regulates different key pathways such as the Notch pathway.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.73 (direct and indirect evidence; datatypes literature 0.89, genetic association 0.21, somatic mutation 0.86). IntOGen calls it a driver in 20 cohorts (1 activating, 18 loss-of-function), covering Acute Myeloid Leukaemia, Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Cervical Squamous Cell Carcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, NOS and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · SPEN (Msx2-interacting protein) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 5 more.
- 1 · What it is
SPEN (Msx2-interacting protein) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 5 more.
- 2 · What goes wrong in cancer
May serve as a nuclear matrix platform that organises and integrates transcriptional responses.
- 3 · How drugs use it
No product in this corpus aims at SPEN yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:17575 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q96T58 (protein name, function text, keywords and locations (REST API)); CIViC gene SPEN (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000065526 (association with cancer (MONDO_0004992) 0.73; per-cancer scores at or above 0.5: colorectal cancer 0.51, melanoma 0.56, acute lymphoblastic leukaemia 0.52, non-Hodgkin lymphoma 0.57, skin cancer 0.56, breast cancer 0.53 (GraphQL API, CC0)); IntOGen SPEN (driver in 20 cohorts (Act 1, LoF 18); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
May serve as a nuclear matrix platform that organises and integrates transcriptional responses. In osteoblasts, supports transcription activation: synergises with RUNX2 to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE). Has also been shown to be an essential corepressor protein, which probably regulates different key pathways such as the Notch pathway. Negative regulator of the Notch pathway via its interaction with RBPSUH, which prevents the association between NOTCH1 and RBPSUH, and therefore suppresses the transactivation activity of Notch signalling. Blocks the differentiation of precursor B-cells into marginal zone B-cells. Probably represses transcription via the recruitment of large complexes containing histone deacetylase proteins. Location: Nucleus (UniProt). Locus 1p36.21-p36.13 (HGNC).
- Breast cancer: Open Targets association 0.53 with breast cancer (MONDO_0007254); IntOGen driver in 5 cohorts (BRCA)
- Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 1 cohort (MLYM)
- Renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC)
- Cervical cancer: IntOGen driver in 1 cohort (CESC)
- Nasopharyngeal carcinoma: IntOGen driver in 1 cohort (NPC)
- Prostate cancer: IntOGen driver in 1 cohort (PRAD)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 18 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"SPEN" OR ABSTRACT:"SPEN" OR TITLE:"spen family transcriptional repressor" OR ABSTRACT:"spen family transcriptional repressor" OR TITLE:"Msx2-interacting protein" OR ABSTRACT:"Msx2-interacting protein" OR TITLE:"KIAA0929" OR ABSTRACT:"KIAA0929" OR TITLE:"SHARP" OR ABSTRACT:"SHARP" OR TITLE:"RBM15C" OR ABSTRACT:"RBM15C") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SPEN, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCASP8
Shares Nasopharyngeal carcinoma, Skin cancer (all types), Non-Hodgkin lymphoma (all types), Cervical cancer.
- TargetNOTCH2
Shares Salivary gland cancers, Skin cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetKAT6B
Shares Nasopharyngeal carcinoma, Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetCYLD
Shares Nasopharyngeal carcinoma, Renal cell carcinoma, Breast cancer (all types), IntOGen.
- TargetTET1
Shares Nasopharyngeal carcinoma, Skin cancer (all types), Renal cell carcinoma, CIViC.
- TargetFAT1
Shares Nasopharyngeal carcinoma, Cervical cancer, Breast cancer (all types), CIViC.
- TargetNOTCH1
Shares Salivary gland cancers, Non-Hodgkin lymphoma (all types), Cervical cancer, CIViC.
- TargetZNF331
Shares Nasopharyngeal carcinoma, Skin cancer (all types), IntOGen, Open Targets Platform.